MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.9 4.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.77

Max

2.92

Põhinäitajad
By Trading Economics
Sissetulek	22M 9.7M
Müük	586K 718K
Kasumimarginaal	1,345.822
Töötajad	23
EBITDA	-152K -12M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+78.57% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	283M 421M
Eelmine avamishind	-1.42
Eelmine sulgemishind	2.9

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.275 / 0.33 Toetus ja vastupanu

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. apr 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17. apr 2026, 18:15 UTC

Uudisväärsed sündmused

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15B

17. apr 2026, 19:34 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

17. apr 2026, 19:34 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17. apr 2026, 19:31 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17. apr 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17. apr 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17. apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. apr 2026, 18:57 UTC

Uudisväärsed sündmused

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB 2026 Rev Guidance Unchanged

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17. apr 2026, 18:14 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17. apr 2026, 17:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17. apr 2026, 17:26 UTC

Market Talk

Tulu

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

78.57% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 78.57%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.